Title
Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)
Non-ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: a Randomized Controlled Split-face Study
Phase
Phase 2Lead Sponsor
Netherlands Institute for Pigment DisordersStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Pigmentation DisorderIntervention/Treatment
hydroquinone triamcinolone tretinoin ...Study Participants
29The purpose of this study is to determine whether the use of non-ablative fractional laser is safe and effective in the treatment of melasma.
1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions. Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy.
In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks. Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy.
Inclusion Criteria: Melasma Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders Age at least 18 years Subject is willing and able to give written informed consent Exclusion Criteria: use of bleaching creams during the past six weeks history of keloid active eczema suspected hypersensitivity to lidocaine or triple therapy use of isotretinoin in the past six months high exposure of the lesion to sunlight or UV light (UVA or UVB).
